



**Anastasios Stathis**

**Kontakt**

Anastasios Stathis

## Publikationen (12)

Spriano F, Sartori G, Sgrignani J, Barnabei L, Arribas A, Guala M, Del Amor A, Tomasso M, Tarantelli C, Cascione L, Golino G, Riveiro M, Bortolozzi R, Lupia A, Paduano F, Huguet S, Rezai K, Rinaldi A, Margheriti F, Ventura-Aguiar P, Guarda G, Costa G, Rocca R, Furlan A, Verdonk L, Innocenti P, Martin N, Viola G, Driessen C, Zucca E, Stathis A, Gahtory D, Van den Nieuwboer M, Bornhauser B, Alcaro S, Trapasso F, Cristobal S, Padrick S, Pazzi N, Cavalli F, Cavalli A, Gaudio E, Bertoni F. A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers. *Haematologica* 2024

Mc Laughlin A, Hess D, Michelet R, Colombo I, Haefliger S, Bastian S, Rabaglio-Poretti M, Schwitter M, Fischer S, Eckhardt K, Hayoz S, Kopp C, Klose M, Sessa C, Stathis A, Halbherr S, Huisinga W, Jörger M, Kloft C. Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial. *Cancer Chemother Pharmacol* 2024; 94:349-360.

Colombo I, Koster K, Holer L, Haefliger S, Rabaglio-Poretti M, Bastian S, Schwitter M, Eckhardt K, Hayoz S, Mc Laughlin A, Kloft C, Klose M, Halbherr S, Baumgartner C, Sessa C, Stathis A, Hess D, Jörger M. TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16). *Eur J Cancer* 2024; 201:113588.

Hanna G, Stathis A, Lopez-Miranda E, Racca F, Quon D, Leyvraz S, Hess D, Keam B, Rodón J, Ahn M, Kim H, Schneeweiss A, Ribera J, DeAngelo D, Perez Garcia J, Cortes J, Schönborn-Kellenberger O, Weber D, Pisa P, Bauer M, Beni L, Bobadilla M, Lehal R, Vigolo M, Vogl F, Garralda E. A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors. *Cancer Res Commun* 2023; 3:1853-1861.

Jörger M, Hundsberger T, Haefliger S, von Moos R, Hottinger A, Kaindl T, Engelhardt M, Marszewska M, Lane H, Roth P, Stathis A. Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study. *Invest New Drugs* 2023; 41:267-275.

Stathis A, Mey U, Schär S, Hitz F, Pott C, Mach N, Krasniqi F, Novak U, Schmidt C, Hohloch K, Kienle D, Hess D, Moccia A, Unterhalt M, Eckhardt K, Hayoz S, Forestieri G, Rossi D, Dirnhofer S, Ceriani L, Sartori G, Bertoni F, Buske C, Zucca E, Hiddemann W. SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma. *Blood Adv* 2022; 6:3911-3920.

Jörger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt A, Cantoni N, Caspar C, Stettler S, Malval R, Pless M, Britschgi C, Renner C, Koeberle D, Schulz J, Kopp C, Hayoz S, Stathis A, von Moos R, Swiss Group for Clinical Cancer Research (SAKK). Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA). *Cancers (Basel)* 2022; 14

Bonfiglio F, Bruscazzin A, Guidetti F, Terzi di Bergamo L, Faderl M, Spina V, Condoluci A, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Piroso M, Cittone M, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista M, Bastidas G, Beà S, Boldorini R, Broccoli A, Buehler M, Canzonieri V, Cascione L, Ceriani L, Cogliatti S, Corradini P, Derenzini E, Devizzi L, Dietrich S, Elia A, Facchetti F, Gaidano G, Garcia J, Gerber B, Ghia P, Gomes da Silva M, Gritti G, Guidetti A, Hitz F, Inghirami G, Ladetto M, López-Guillermo A, Lucchini E, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia A, Mollejo M, Montalban C, Novak U, Oscier D, Passamonti F, Piazza F, Pizzolitto S, Rambaldi A, Sabattini E, Salles G, Santambrogio E, Scarfo L, Stathis A, Stussi G, Geyer J, Tapia G, Tarella C, Thieblemont C, Tousseyn T, Tucci A, Vanini G, Visco C, Vitolo U, Walewska R, Zaja F, Zenz T, Zinzani P, Khiabanian H, Calcinotto A, Bertoni F, Bhagat G, Campo E, de Leval L, Dirnhofer S, Pileri S, Piris M, Traverse-Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F, Zucca E, Rossi D. Genetic and phenotypic attributes of splenic marginal zone lymphoma. *Blood* 2022; 139:732-747.

Piroso M, Zhang L, Hitz F, Novak U, Hess D, Terrot T, Pascale M, Mazzucchelli L, Bertoni F, Cavalli F, Zucca E, Stathis A. A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas. *Leuk Lymphoma* 2021; 63:117-123.

Jörger M, Sessa C, Stuedeli S, Levy N, Hafner P, Lane H, Larger P, Engelhardt M, Kaindl T, Volden M, Mark M, Mantiero M, Hess D, Metaxas Y, Stathis A, von Moos R. A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors. *Invest New Drugs* 2019

Gobba S, Gaidano G, Pinotti G, Hitz F, Stathis A, Aprile von Hohenstaufen K, Margiotta-Casaluci G, Iacoboni G, Cascione L, Diem S, Conconi A, Gulden-Sala W, Moccia A, Zucca E. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions. *Hematol Oncol* 2017

Ribi K, Rondeau S, Hitz F, Mey U, Enoiu M, Pabst T, Stathis A, Fischer N, Clough-Gorr K. Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma. *Support Care Cancer* 2017; 25:2833-2842.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)